Jorge Nieva

Please join me on March 17th at the Lung Cancer Living Room where we will be discussing clinical trials. events.go2.org/2026MarchLivin…

@danielanieva/note/c-212680280?r=1gdu73&utm_medium=ios&utm_source=notes-share-action" target="_blank" rel="nofollow noopener">substack.com/@danielanieva/…

First-line #NSCLC care has evolved. In a conversation with @ADesaiMD (@ONealCancerUAB), @nievamd (@uscnorris) explains how patient priorities shape treatment intensification: bit.ly/4aTBGuG #NSCLC #CancerCare

Great work by one of our outstanding graduate students. authors.elsevier.com/c/1m5Ev5QwJC0L…

Happy to see this important work on real world data of uncommon EGFR mutations publically available. link.springer.com/article/10.100…

🫁 As Lung Cancer Awareness Month continues, don't miss this insightful interview with @nievamd of @KeckMedicineUSC, who reflects on the importance of #LCAM, the cultural shift he's seen around lung cancer, and why screening is critical. ➡️ Watch: buff.ly/BsXjTto #lcsm

@danielanieva/note/p-172977918?r=1gdu73&utm_medium=ios&utm_source=notes-share-action" target="_blank" rel="nofollow noopener">substack.com/@danielanieva/…

Advancing new drugs to patients is important. But equally important is ensuring that drug toxicity is minimized. Very proud to have been part of this important study. jto.org/article/S1556-…

My daughter has launched a sub stack project and is proving herself to be a terrific writer. I invite you all to read it and subscribe if you want to see more. bordersunbound.substack.com

Very proud of Rahul Mudumba for completing this important pharmaco-economic analysis of ALK fusion lung cancer treatment. jmcp.org/doi/full/10.18…

💊 How do steroids impact survival in patients undergoing immunotherapy for NSCLC? 🫁 Don't miss this insightful interview with @nievamd of @KeckMedicineUSC, who discusses recent bedside-to-bench research that addressed the question. ➡️ Watch: buff.ly/FI2FBsS #lcsm

Greetings from Huntington Beach, CA.

Diving beyond EGFR in NSCLC with an excellent session chaired by @SchenkLab, featuring a stellar lineup of talks on KRAS, BRAF, ROS1, MET, RET, and more! With insights from @christinemphmd @drgandara @mihaela_aldea @nievamd @riess_md @OncLive #BTGLung2025 #LCSM #Oncology

A huge thanks to @nievamd, of @KECKSchool_USC, who stopped by during #BTGLung2025 to talk about the management of ALK rearrangements in NSCLC! Check out our site for exclusive insights from Dr Nieva and more! #lcsm #oncology onclive.com/bridging-the-g…

‼️Polling Q2. Emerging treatment options in SCLC What do you see as the most promising strategy to improve OS in SCLC? #BTGLung2025 @sands_jacob @triparnasen @NarjustFlorezMD @DrEdKim @AnaVManana @OncLive

Join OncLive LIVE July 23, 3:30 PM PT. Engage w/ Narjust Florez, MD, Edward S. Kim, MD, Eric K. Singhi, MD & vote in interactive polls! See how your answers align w/ experts. Follow @OncLive & click 🔔 for alerts! #BTGLung2025 @lungoncdoc @DrEdKim @NarjustFlorezMD

The FDA has approved taletrectinib for ROS1+ NSCLC, but what does that mean for clinical practice? On #LungCancerConsidered, @StephenVLiu, @EnriquetaFelip & @nievamd discuss this approval & how to position taletrectinib among treatment options. 🎧 bit.ly/FDATaletrectin…

Tune in tomorrow for the latest episode of the @IASLC podcast, Lung Cancer Considered, where I discuss the recent FDA approval of taletrectinib in #ROS1 NSCLC, with Drs. @nievamd and @EnriquetaFelip. Where will this drug fit into the treatment landscape? Download tomorrow!